Coherus BioSciences Provides Update on IPRs
June 13 2016 - 2:04PM
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play,
global biosimilars company with late-stage clinical products, today
announced that it has received a favorable decision from the Patent
Trial and Appeal Board (PTAB) of the US Patent and Trademark office
instituting Coherus’ petitions for Inter Partes Review (IPR) of
AbbVie’s U.S. Patents 9,017,680 and 9,073,987 (Patents ‘680
and ‘987, respectively) related to the dosing regimen for AbbVie’s
Humira (adalimumab) to treat rheumatoid arthritis.
“We are pleased by today’s decision by the PTAB to institute
formal IPR proceedings related to patents ‘680 and ‘987. It
is important to note that a panel of PTAB judges, different and
independent from those that instituted our IPR on U.S. Patent
8,889,135, has provided further validation of the merits of
Coherus’ arguments. We remain confident that these patents
will be invalidated, de-risking our projected launch in 2018,” said
Denny Lanfear, President and Chief Executive Officer of Coherus.
“Coherus is committed to our position as an industry leader
in the development of vibrant biosimilar market both in the United
States, and abroad. We will continue to aggressively press
forward with the development and commercialization of our Humira
biosimilar consistent with our corporate strategy.”
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform
company that develops and commercializes high-quality therapeutics
for major regulated markets. Biosimilars are intended for use in
place of existing, branded biologics to treat a range of chronic
and often life-threatening diseases, with the potential to reduce
costs and expand patient access. Composed of a team of proven
industry veterans with world-class expertise in process science,
analytical characterization, protein production and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products, including CHS-5217 (bevacizumab
biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional
information, please visit www.coherus.com.
Forward-Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release, including statements
regarding Coherus’ plans, potential opportunities, expectations,
projections, goals, objectives, milestones, strategies, product
pipeline, clinical studies, product development, release of data
and the potential benefits of its products under development are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including Coherus’ expectations regarding its ability to advance
its intellectual strategy for CHS-1420 including a final decision
nullifying the ‘135, ‘680 and ‘987 Patents, to complete CHS-1420
development and to initiate CHS-1420 commercialization. Such
forward-looking statements involve substantial risks and
uncertainties that could cause our clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the
uncertainties inherent in the clinical drug development process,
including the regulatory approval process, the timing of our
regulatory filings and other matters that could affect the
availability or commercial potential of our biosimilar drug
candidates, as well as possible patent litigation. Coherus
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, see Coherus’ Annual
Report on Form 10-Q for the quarter ended March 31, 2016, filed
with the Securities and Exchange Commission on May 9, 2016 and its
future periodic reports to be filed with the Securities and
Exchange Commission.
HUMIRA® is a registered trademark of AbbVie Inc.
CONTACT:
Investors:
Patrick O’Brien
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Media:
Megan Humphreys
McBee Strategic
mhumphreys@mcbeestrategic.com
+1(202) 465-7753
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024